Annovis Bio Closes Underwritten Public Offering Raising ~$10M In Gross Proceeds; Financing Secures Path To First NDA Submission For Buntanetap

• Financing secures path to first NDA submission for buntanetap
• 6-Month symptomatic data readout anticipated Q1 2027
• Alzheimer's disease Phase 3 trial 75% enrolled
• Parkinson's disease open-label study 28% enrolled

MALVERN, Pa., April 10, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the closing of an underwritten public offering raising approximately $10 million in gross proceeds. Combined with existing cash on hand as well as a recent $1.5 million investment from the Board of Directors Chair, Michael Hoffman, the financing extends Annovis' cash runway through Q2 2027, fully funding the Company's operations through a key symptomatic data readout of its Phase 3 AD trial and the anticipated submission of a New Drug Application (NDA) for buntanetap to the U.S. Food and Drug Administration (FDA).